A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
- PMID: 31738483
- DOI: 10.1056/NEJMoa1910355
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Abstract
Background: The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied.
Methods: In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3 months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.8 mmol per liter) (lower-target group) or to a target range of 90 mg to 110 mg per deciliter (2.3 to 2.8 mmol per liter) (higher-target group). All the patients had evidence of cerebrovascular or coronary-artery atherosclerosis and received a statin, ezetimibe, or both. The composite primary end point of major cardiovascular events included ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid revascularization, or death from cardiovascular causes.
Results: A total of 2860 patients were enrolled and followed for a median of 3.5 years; 1430 were assigned to each LDL cholesterol target group. The mean LDL cholesterol level at baseline was 135 mg per deciliter (3.5 mmol per liter), and the mean achieved LDL cholesterol level was 65 mg per deciliter (1.7 mmol per liter) in the lower-target group and 96 mg per deciliter (2.5 mmol per liter) in the higher-target group. The trial was stopped for administrative reasons after 277 of an anticipated 385 end-point events had occurred. The composite primary end point occurred in 121 patients (8.5%) in the lower-target group and in 156 (10.9%) in the higher-target group (adjusted hazard ratio, 0.78; 95% confidence interval, 0.61 to 0.98; P = 0.04). The incidence of intracranial hemorrhage and newly diagnosed diabetes did not differ significantly between the two groups.
Conclusions: After an ischemic stroke or TIA with evidence of atherosclerosis, patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those who had a target range of 90 mg to 110 mg per deciliter. (Funded by the French Ministry of Health and others; Treat Stroke to Target ClinicalTrials.gov number, NCT01252875.).
Copyright © 2019 Massachusetts Medical Society.
Comment in
-
Statins and Stroke - It's Complicated.N Engl J Med. 2020 Jan 2;382(1):81-82. doi: 10.1056/NEJMe1914757. Epub 2019 Nov 18. N Engl J Med. 2020. PMID: 31738482 No abstract available.
-
Cholesterinsenkung: Neue Evidenz für Zielwerte : Herz-Kreislauf-Gesundheit.MMW Fortschr Med. 2020 Apr;162(6):28-29. doi: 10.1007/s15006-020-0325-y. MMW Fortschr Med. 2020. PMID: 32248486 Review. German. No abstract available.
-
LDL Cholesterol Targets after Ischemic Stroke.N Engl J Med. 2020 Apr 9;382(15):1480. doi: 10.1056/NEJMc2001195. N Engl J Med. 2020. PMID: 32268035 No abstract available.
-
Intensive Lipidsenkung heißt mindestens LDL < 70 mg/dl : Schlaganfallrisiko.MMW Fortschr Med. 2020 Jun;162(12):24-25. doi: 10.1007/s15006-020-0602-9. MMW Fortschr Med. 2020. PMID: 32578105 Review. German. No abstract available.
-
Can we trust trials with such features?Epidemiol Prev. 2022 Jan-Apr;46(1-2):3. doi: 10.19191/EP22.1-2.P003.004. Epidemiol Prev. 2022. PMID: 35354257 English. No abstract available.
Similar articles
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. N Engl J Med. 2011. PMID: 22085343 Clinical Trial.
-
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Clinical Trial.
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.
-
2017 Taiwan lipid guidelines for high risk patients.J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. J Formos Med Assoc. 2017. PMID: 28242176 Review.
-
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.JAMA. 2018 Apr 17;319(15):1566-1579. doi: 10.1001/jama.2018.2525. JAMA. 2018. PMID: 29677301 Free PMC article. Review.
Cited by
-
Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention.Nat Rev Neurol. 2024 Nov 15. doi: 10.1038/s41582-024-01035-w. Online ahead of print. Nat Rev Neurol. 2024. PMID: 39548285 Review.
-
Beyond low-density lipoprotein cholesterol levels: Impact of prior statin treatment on ischemic stroke outcomes.Innovation (Camb). 2024 Oct 10;5(6):100713. doi: 10.1016/j.xinn.2024.100713. eCollection 2024 Nov 4. Innovation (Camb). 2024. PMID: 39524491 Free PMC article.
-
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence.Curr Atheroscler Rep. 2024 Nov 9;27(1):2. doi: 10.1007/s11883-024-01255-x. Curr Atheroscler Rep. 2024. PMID: 39520593 Free PMC article. Review.
-
Temporal trends of the burden of ischemic stroke attributable to high low-density lipoprotein cholesterol in China from 1999 to 2019.BMC Public Health. 2024 Oct 30;24(1):3003. doi: 10.1186/s12889-024-20461-5. BMC Public Health. 2024. PMID: 39478553 Free PMC article.
-
Impact of non-traditional lipid profiles on 1-year vascular outcomes in ischemic stroke patients with prior statin therapy and LDL-C < 100 mg/dL.Sci Rep. 2024 Oct 1;14(1):22794. doi: 10.1038/s41598-024-73851-5. Sci Rep. 2024. PMID: 39354143 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical